The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | The impact of SF3B1 mutation in myelofibrosis
Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of SF3B1 mutation in myelofibrosis (MF) and other myeloid malignancies. Dr Bose first comments on the impact of this mutation on patients with myelodysplastic syndromes (MDS), and then explains how this mutation impacts patients with MF. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
